Nanoviricides (NNVC) Other Non-Current Assets (2013 - 2023)
Nanoviricides (NNVC) posted Other Non-Current Assets of $14361.0 for Q2 2023, down 25.14% sequentially from $19183.0 in Q1 2023, and up 308.56% YoY from $3515.0 in Q2 2022.
Nanoviricides (NNVC) Other Non-Current Assets (2013 - 2023) Analysis & Trends
Nanoviricides has reported Other Non-Current Assets for 10 years, with the latest figure at $14361.0 in Q2 2023.
- Quarterly Other Non-Current Assets rose 308.56% year-over-year to $14361.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $14361.0 (up 308.56% YoY) and the FY2023 annual result came in at $14361.0, up 308.56% from the prior year.
- Other Non-Current Assets slipped to $14361.0 in Q2 2023 per NNVC's latest filing, from $19183.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $62977.0 in Q3 2020 and troughed at $3515.0 in Q1 2021.
- A 5-year average of $18022.3 and a median of $15930.0 in 2020 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Other Non-Current Assets tumbled 94.42% in 2021, then soared 1300.2% in 2022.
- Over 5 years, Other Non-Current Assets stood at $21367.0 in 2019, then tumbled by 72.61% to $5853.0 in 2020, then tumbled by 39.95% to $3515.0 in 2021, then surged by 654.2% to $26510.0 in 2022, then plunged by 45.83% to $14361.0 in 2023.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $14361.0, $19183.0, and $26510.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 14,361.00 |
| Mar 31, 2023 | 19,183.00 |
| Dec 31, 2022 | 26,510.00 |
| Sep 30, 2022 | 3,515.00 |
| Jun 30, 2022 | 3,515.00 |
| Mar 31, 2022 | 49,217.00 |
| Dec 31, 2021 | 3,515.00 |
| Sep 30, 2021 | 3,515.00 |
| Jun 30, 2021 | 3,515.00 |
| Mar 31, 2021 | 3,515.00 |
| Dec 31, 2020 | 5,853.00 |
| Sep 30, 2020 | 62,977.00 |
| Jun 30, 2020 | 25,863.00 |
| Mar 31, 2020 | 17,499.00 |
| Dec 31, 2019 | 21,367.00 |
| Sep 30, 2019 | 25,277.00 |
| Jun 30, 2019 | 29,187.00 |
| Mar 31, 2019 | 6,017.00 |
| Dec 31, 2018 | 3,515.00 |
| Sep 30, 2018 | 6,737.00 |